The promise of CD40L blockers is to modulate the immune system rather than suppress it. Traditional immunosuppression drugs ...

For Biogen, dapirolizumab pegol is part of a push ... "Our hypothesis is that impacting the CD40L pathway, a central mechanism in immune response, would translate to significant impact on SLE ...

“Anti-CD40L modulates T cell function and has the potential to ... PMID: 38354138 2 Gelman, M. Endpoints. “Biogen, UCB detail response rates in Phase 3 lupus trial after surprising Success” Nov. 19, ...

I'm Marc Goodman, one of the biopharma analyst, and we're lucky to have Biogen with us here, Alisha Alaimo, who is the President of North America. Thank you very much for joining us. Well ...

Biogen has finalised a $900 million payment to settle a whistleblower lawsuit claiming that it paid kickbacks to US doctors to prescribe its multiple sclerosis drugs.

March 11, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – announced the initiation of dosing in the global clinical study, TRANSCEND. The Phase 3 study will evaluate the efficacy and safety of ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

After hours: 13 March at 7:37:36 pm GMT-4 Loading Chart for BIIB ...

Pre-Market: 5:58:06 a.m. EDT Loading Chart for BIIB ...